Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. We focus on how molecular interaction analysis and structural information can improve and advance the development of high quality, small molecule drug leads.

As well as progressing its own drug discovery programmes, Beactica offers partnerships for fragment-based lead generation using its proprietary discovery platformand services in the area of SPR biosensor-based interaction analysis.

Beactica AB is a privately held company founded in 2006 by Per Källblad, Ph.D., previously at Medivir AB, and Prof. Helena Danielson at Uppsala University. The company is based in Uppsala, Sweden and has received funding from the European Union, the Swedish Governmental Agency for Innovation Systems (VINNOVA), Uppsala University Holding Company and ALMI Invest.

If you are interested in Beactica – whether you’re a potential client, investor or employee – we’ll always be delighted to hear from you.